Global leader in therapeutic ultrasound and present in the market for close to 40 years, EDAP TMS (NASDAQ: EDAP) develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology. EDAP TMS is actively operating worldwide via an extensive network of corporate offices, subsidiaries and distribution partners.

By constantly investing in Research & Development and partnering with internationally renowned medical research institutions, EDAP TMS has developed a strong valuable patent portfolio based on its innovative technologies.

With its complete range of Robotic HIFU devices, EDAP TMS is the most innovative company in minimally-invasive treatment for localized prostate cancer. By combining the latest technologies in imaging and treatment modalities, EDAP TMS just introduced the Focal One® as the answer to all requirements for ideal focal therapy of prostate cancer as a complement to the existing Ablatherm® HIFU.

As a pioneer and key player in the field of extracorporeal lithotripsy (ESWL), EDAP TMS introduced the first modular lithotripter. The latest generation of shock wave source is utilized exclusively by EDAP TMS in its Sonolith® range of ESWL systems (Sonolith® i-sys and Sonolith® i-move).

Established in 1975 in Northern California, Eigen is improving healthcare and quality of life through innovative breakthroughs in image-guided disease diagnosis and treatment. With a focus on research & development and medical device manufacturing, Eigen currently holds over 50 patents.

Eigen adheres to the highest standard in medical device regulatory compliance. Eigen places great importance on effective risk management, as well as the best practices specific to safe medical device design, manufacture and installation. Eigen prides itself on providing excellent training to the doctors using our device. Eigen is FDA cleared, CE and TGA approved and has ISO 13485 certification.

Eigen’s MRI/US fusion, PET-CT/US fusion and 3D navigation technology has been validated by multiple reputed universities worldwide and its results published in many top peer-reviewed journals. Eigen’s technology allows for accurate targeting, recording and sampling of lesions for diagnosis as well as for follow up in active surveillance or focal therapy.

Exact Imaging’s ExactVu™ 29 MHz micro-ultrasound platform provides a 300% improvement in resolution over conventional ultrasound enabling real-time targeted prostate biopsies. It is simple, affordable, and an extension of the current urological workflow. PRI-MUS™ (prostate risk identification using micro-ultrasound) is an evidence-based scale to help urologists identify relevant tissue characteristics using micro-ultrasound imaging and was developed to standardize reporting and terminology for micro-ultrasound images of the prostate. For those cases where MRI might assist, the FusionVu™ micro-US/MRI fusion application operates on the same hardware platform - - and is guided by the real-time 70 micron resolution of the ExactVu system.
Rob Sandler
SVP, Marketing
Exact Imaging
C. +1.416.274.8166
E. rsandler@exactimaging.com
W. www.exactimaging.com